Wall Street Icon: “You must get on the right side of this thing”

I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.

This market shakeup is going to be much more intense.

James Bristol Biography and Net Worth

Director of Deciphera Pharmaceuticals

Dr. James Arthur Bristol Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Bristol has served as a member of our Board of Directors since August 2007, as Chairperson since February 2015 and as co-Chairperson from September 2007 to February 2015. Dr. Bristol has also served as Chairperson of the Compensation Committee since September 2017. Dr. Bristol worked for 32 years in drug discovery, research and preclinical development at Schering-Plough Corporation, Parke-Davis, and Pfizer Inc., serving in various senior research and development roles. From 2003 until his retirement in 2007, Dr. Bristol served as Senior Vice President of Worldwide Drug Discovery Research at Pfizer Global Research & Development, where he oversaw 3,000 scientists at seven Pfizer sites as they produced an industry leading number of drug development candidates in 11 therapeutic areas. In 2009, Dr. Bristol joined Frazier Healthcare Ventures as a Senior Advisor. He has served as director of Ignyta, Inc. from 2014 to 2018, Erasca, Inc. since 2018, and Cadent Therapeutics, Inc. since 2011. Dr. Bristol is the author of over 100 publications, abstracts and patents, and he conducted postdoctoral research at the University of Michigan (NIH Postdoctoral Fellow) and at The Squibb Institute for Medical Research. Dr. Bristol holds a Ph.D. in organic chemistry from the University of New Hampshire and a B.S. in Chemistry from Bates College.

What is James Arthur Bristol's net worth?: The estimated net worth of James Arthur Bristol is at least $135,627.00 as of April 19th, 2021. Dr. Bristol owns 5,300 shares of Deciphera Pharmaceuticals stock worth more than $135,627 as of December 16th. This net worth estimate does not reflect any other assets that Dr. Bristol may own. Learn More about James Arthur Bristol's net worth.
How do I contact James Arthur Bristol?: The corporate mailing address for Dr. Bristol and other Deciphera Pharmaceuticals executives is 200 SMITH STREET, Waltham MA, 02451. Deciphera Pharmaceuticals can also be reached via phone at (781) 209-6400 and via email at [email protected]. Learn More on James Arthur Bristol's contact information.
Has James Arthur Bristol been buying or selling shares of Deciphera Pharmaceuticals?: James Arthur Bristol has not been actively trading shares of Deciphera Pharmaceuticals over the course of the past ninety days. Most recently, James Arthur Bristol sold 5,300 shares of the business's stock in a transaction on Monday, April 19th. The shares were sold at an average price of $46.26, for a transaction totalling $245,178.00. Following the completion of the sale, the director now directly owns 5,300 shares of the company's stock, valued at $245,178. Learn More on James Arthur Bristol's trading history.
Who are Deciphera Pharmaceuticals' active insiders?: Deciphera Pharmaceuticals' insider roster includes James Bristol (Director), Daniel Flynn (Insider), Thomas Kelly (CFO), Matthew Sherman (EVP), and Michael Taylor (Director). Learn More on Deciphera Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Deciphera Pharmaceuticals?: In the last year, insiders at the sold shares 2 times. They sold a total of 4,059 shares worth more than $58,733.73. The most recent insider tranaction occured on January, 16th when EVP Matthew L Sherman sold 2,435 shares worth more than $35,234.45. Insiders at Deciphera Pharmaceuticals own 4.7% of the company. Learn More about insider trades at Deciphera Pharmaceuticals.
Information on this page was last updated on 1/16/2024.

James Arthur Bristol Insider Trading History at Deciphera Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/19/2021	Sell	5,300	$46.26	$245,178.00	5,300
4/12/2021	Sell	14,700	$43.84	$644,448.00	14,700
7/9/2020	Sell	23,541	$54.99	$1,294,519.59	16,324
4/9/2020	Sell	23,542	$43.83	$1,031,845.86	23,542
11/1/2019	Sell	25,000	$46.16	$1,154,000.00
2/15/2019	Sell	18,883	$28.04	$529,479.32
2/13/2019	Sell	3,522	$28.01	$98,651.22
2/5/2019	Sell	2,595	$28.02	$72,711.90

James Arthur Bristol Buying and Selling Activity at Deciphera Pharmaceuticals

Deciphera Pharmaceuticals Company Overview

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $25.59

$25.59

50 Day Range

MA: $25.59

$25.55

$25.59

2 Week Range

Now: $25.59

$9.90

$25.61

Volume

600 shs

Average Volume

1,292,551 shs

Market Capitalization

$2.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.19